New drug cocktail shows promise against tough blood cancers

NCT ID NCT04047641

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study combines three chemotherapy drugs (cladribine, idarubicin, cytarabine) with a targeted drug (quizartinib) to treat acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). It includes up to 80 adults who are newly diagnosed or whose cancer has returned or not responded to prior treatment. The goal is to see if this combination improves event-free survival and overall survival while monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute myeloid leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA BLASTS 20 PERCENT OR MORE OF BONE MARROW NUCLEATED CELLS HIGH RISK MYELODYSPLASTIC SYNDROME RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT HIGH RISK MYELODYSPLASTIC SYNDROME REFRACTORY ACUTE MYELOID LEUKEMIA REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-••••

Contact